Abiomed (NASDAQ: ABMD) is a pioneer and global leader in healthcare technology and innovation, with a mission of RECOVERING HEARTS AND SAVING LIVES. Abiomed CEO, Chairman, and President, Michael R. Minogue, has focused the company’s efforts on developing ground-breaking technologies designed to assist or replace the life-sustaining pumping function of the failing heart. The Company’s portfolio of products and services offer healthcare professionals an array of choices across a broad clinical spectrum. From the world’s first total replacement heart to the World’s Smallest Heart Pump, 1/100th the size of the heart with rapid and simple insertion, Abiomed is dedicated to finding ways to bring the most advanced and beneficial technology to patients and physicians.
Danvers, US
Size (employees)
747 (est)+27%
ABIOMED is headquartered in Danvers, US

ABIOMED Office Locations

ABIOMED has offices in Danvers, Aachen
Danvers, US
Aachen, DE



Market capitalization

$5.4 b

Closing share price

ABIOMED's current market capitalization is $5.4 b.

ABIOMED Financials

ABIOMED's revenue is $183.6 m in FY, 2014 which is a 20.3% decrease from the previous period.
FY, 2014FY, 2015Y, 2016


$183.6 m$230.3 m$329.5 m

Revenue growth, %


Gross profit

$146.3 m$190.4 m

Operating expense total

$138 m$161.7 m


$8.4 m$28.7 m

Net Income

$7.4 m$113.7 m

Operating cash flow

$11.5 m$1.5 m

ABIOMED Market Value History

ABIOMED Online Presence

ABIOMED Company Life

You may also be interested in